Pichai Raman on behalf of cBioPortal Team Wednesday, May 25, 16

Slides:



Advertisements
Similar presentations
Data Visualization in Molecular Biology Alexander Lex July 29, 2013.
Advertisements

Presented by Karen Xu. Introduction Cancer is commonly referred to as the “disease of the genes” Cancer may be favored by genetic predisposition, but.
Clinical Trials, TCGA: Deep Integrative Research RT, Imaging, Pathology, “omics” Joel Saltz MD, PhD Director Center for Comprehensive Informatics.
Gene expression profiling identifies molecular subtypes of gliomas
Cancer is heterogeneous disease! -> enabled characterization of new tumor subtypes for improving personalized treatment and ultimately achieving better.
Radiogenomics in glioblastoma multiforme
Basic features for portal users. Agenda - Basic features Overview –features and navigation Browsing data –Files and Samples Gene Summary pages Performing.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Genboree Discovery Process Integration Aleksandar Milosavljevic, PhD Baylor College of Medicine January 10 th, 2008; modified April 1 st 2008.
Sage Bionetworks A non-profit organization with a vision to enable networked team approaches to building better models of disease BIOMEDICINE INFORMATION.
Lecture 11. Topics in Omic Studies (Cancer Genomics, Transcriptomics and Epignomics) The Chinese University of Hong Kong CSCI5050 Bioinformatics and Computational.
CBioPortal Web resource for exploring, visualizing, and analyzing multidimentional cancer genomics data.
INTERPRETING GENETIC MUTATIONAL DATA FOR CLINICAL ONCOLOGY Ben Ho Park, M.D., Ph.D. Associate Professor of Oncology Johns Hopkins University May 2014.
(1) Genotype-Tissue Expression (GTEx) Largest systematic study of genetic regulation in multiple tissues to date 53 tissues, 500+ donors, 9K samples, 180M.
An Overview of The Cancer Genome Atlas (TCGA)
DNA Microarray. Microarray Printing 96-well-plate (PCR Products) 384-well print-plate Microarray.
IDENTIFYING CANCER SUBTYPES BASED ON SOMATIC MUTATION PROFILE BIOINFORMATICS SEMINAR 2016 SPRING YOUJIN SHIN.
San Antonio Breast Cancer Symposium – December 6-10, 2016
David Amar, Tom Hait, and Ron Shamir
To develop the scientific evidence base that will lessen the burden of cancer in the United States and around the world. NCI Mission Key message:
014 - Evaluation of Immunosignature Profile in Medulloblastoma
Sungkyunkwan University, School of Medicine.
NCT: Gaining Medical Insights and Enhancing Care for Cancer Patients with SAP HANA® Organization National Center for Tumor Diseases (NCT) Heidelberg, part.
Solutions to Clinical Data Visualization and Analysis
Cancer Genomics and Class Discovery
SI-II A SI-II. Expression analysis of bladder cancer functionally active genes and significantly mutated genes. Comprehensive transcriptome profiling of.
The PedcBioPortal & DiseaseXpress
Gene expression.
Global Transcriptional Dysregulation in Breast Cancer
Angela J Waanders, MD, MPH The Children’s Hospital of Philadelphia
Sarah Leary, MD MS CBTTC 5/25/2016
NCI’s Genomics Data Commons (GDC) & NCI Cloud Pilots
Dept of Biomedical Informatics University of Pittsburgh
A New Path Forward: Immune Checkpoint Inhibitors in Bladder Cancer
The cBio Cancer Genomics Portal.
Content and Labeling of Tests Marketed as Clinical “Whole-Exome Sequencing” Perspectives from a cancer genetics clinician and clinical lab director Allen.
N. Capp, E. Krome, I. Obeid and J. Picone
Fig. 8. Recurrent copy number amplification of BRD4 gene was observed across common cancers. Recurrent copy number amplification of BRD4 gene was observed.
Strategy Description Discovery Validation Application
Volume 5, Issue 1, Pages (October 2013)
Next-Generation Sequencing
Organizing a Phase 1 Unit in Korea
Volume 27, Issue 3, Pages (March 2015)
Volume 145, Issue 3, Pages (June 2017)
Volume 5, Issue 4, Pages e5 (October 2017)
Volume 17, Issue 1, Pages (January 2010)
Implementing Genome-Driven Oncology
Angela L. Rasmussen, Michael G. Katze  Cell Host & Microbe 
The Genetic Basis for Cancer Treatment Decisions
Volume 31, Issue 2, Pages (February 2017)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Volume 58, Issue 4, Pages (May 2015)
Volume 151, Issue 2, Pages e6 (August 2016)
Histopathological Image QTL Discovery of Immune Infiltration Variants
Volume 24, Issue 8, Pages (August 2018)
Molecular prognostication of liver cancer: End of the beginning
Quality Assurance of RNA Expression Profiling in Clinical Laboratories
Volume 29, Issue 5, Pages (May 2016)
Patterns of Somatically Acquired Amplifications and Deletions in Apparently Normal Tissues of Ovarian Cancer Patients  Leila Aghili, Jasmine Foo, James.
Altered Caspase-8 Expression
Volume 26, Issue 12, Pages e5 (March 2019)
Knowledge-Guided Sample Clustering
Figure 1. Identification of three tumour molecular subtypes in CIT and TCGA cohorts. We used CIT multi-omics data ( Figure 1. Identification of.
Stephen Bridgett, James Campbell, Christopher J. Lord, Colm J. Ryan 
Overall Survival and Progression-free Survival
PD-L1 expression correlates with T-cell markers and an IFN response signature in human melanomas. PD-L1 expression correlates with T-cell markers and an.
One potential implementation for the use of outlier kinase profiling and targeting for clinical management of pancreatic cancer in a precision medicine.
Molecular characterization of esophagogastric tumors.
TME characteristics of TCGA-STAD subtype and cancer somatic genome.
Vylyny Chat, Robert Ferguson, Tomas Kirchhoff 
Presentation transcript:

Pichai Raman on behalf of cBioPortal Team Wednesday, May 25, 16 cBioPortal+ Cancer Visualization & Analytics Application for Research | Translational Science | Clinical Decisions Pichai Raman on behalf of cBioPortal Team Wednesday, May 25, 16

Outline History& Overview Data and Application usage Key Functionality & Features Security & Authentication Coming Attractions

History & Overview Original cBioPortal developed at MSKCC for TCGA data and other large-scale cancer profiling efforts Lowers barrier to access and visualize complex genomic data for research cBioPortal Development now shared across 5 teams : DFCI, MSKCC, Princess Margaret, and CHOP, the Hyve cBioPortal+ : CHOP Implementation has a focus on Pediatric cancer data sets

History & Overview Excels at visualization & presentation of multiple data types in an integrated manner

Data and Application Usage Used Extensively at MSKCC with > 5000 Users a week Type Total MSKCC CHOP Studies 113 91 22 Samples 24026 21334 2692 Data sets are being added on a weekly basis from various sources. Processed through reproducible best practice pipelines.

Data and Application Usage MSKCC currently houses a number of data sources. Used Extensively at MSKCC with > 5000 Users a week SU2C CBTTC BUT WE ARE ADDING MORE TARGET EGA/dbGaP

Key Functionality & Features cBioPortal+ has a number of visualizations based on one of three entry points Study View Display of frequent / recurrent mutations or lesions within a study When creating virtual co-horts of molecular subtypes will be able to quickly identify “potental” drivers Sample View Get an overview of all of a patients genetic lesions, connections to Path Reports, clinical trials, drugs, etc.. Has COSMIC data as well as internal statistics to aid in determining if a mutation is likely causal Gene View Look at gene data (mutation / expression etc..) across or within study Correlate genes to other genes within a study or compare to normal tissue expression Can be used to identify targets for immunotherapy

Key Functionality & Features cBioPortal+ has a number of visualizations based on one of three entry points Study View Display of frequent / recurrent mutations or lesions within a study When creating virtual co-horts of molecular subtypes will be able to quickly identify “potental” drivers Sample View Get an overview of all of a patients genetic lesions, connections to Path Reports, clinical trials, drugs, etc.. Has COSMIC data as well as internal statistics to aid in determining if a mutation is likely causal Gene View Look at gene data (mutation / expression etc..) across or within study Correlate genes to other genes within a study or compare to normal tissue expression Can be used to identify targets for immunotherapy

Mutation Lollipop View Recurrent hotspot identification Height indicates frequency Annotates with COSMIC, cBioPortal Frequencies, and predicts whether mutation event is damaing

Tumor vs Normal Immunotherapy Target Discovery Color indicates significance P-value Cutoff P-value, Tumor vs Normal Median Tumor Expression Visualization for RNA-Seq or Microarray data, with ability to look at raw, log, or z-score normalizations and p-value showing differential

Other Gene View Visuals Mutual Exclusivity Correlation PPI Networks

Key Functionality & Features cBioPortal+ has a number of visualizations based on one of three entry points Study View Display of frequent / recurrent mutations or lesions within a study When creating virtual co-horts of molecular subtypes will be able to quickly identify “potental” drivers Sample View Get an overview of all of a patients genetic lesions, connections to Path Reports, clinical trials, drugs, etc.. Has COSMIC data as well as internal statistics to aid in determining if a mutation is likely causal Gene View Look at gene data (mutation / expression etc..) across or within study Correlate genes to other genes within a study or compare to normal tissue expression Can be used to identify targets for immunotherapy

Descriptive statistics on cohort Summary Page Overview Recurrent CNV Recurrent Mutations Descriptive statistics on cohort

Selection of Samples Survival Plot Select Genes and all samples with a mutation become a group for Survival Plot

Clinical Data Table Tabular view to find Samples Clinical data sortable and searchable Can click on sample to get to sample view

Key Functionality & Features cBioPortal+ has a number of visualizations based on one of three entry points Study View Display of frequent / recurrent mutations or lesions within a study When creating virtual co-horts of molecular subtypes will be able to quickly identify “potental” drivers Sample View Get an overview of all of a patients genetic lesions, connections to Path Reports, clinical trials, drugs, etc.. Has COSMIC data as well as internal statistics to aid in determining if a mutation is likely causal Gene View Look at gene data (mutation / expression etc..) across or within study Correlate genes to other genes within a study or compare to normal tissue expression Can be used to identify targets for immunotherapy

Clinical Trials and additional tabs Patient Summary Page Add to Harvest Cart Mutation & CNA table Clinical Trials and additional tabs Genome View

Patient View Harvest Cart Integration Clicking submit takes you to CBTTC Harvest application with desired samples loaded Samples Added to the bucket can be accessed via the HARVEST CART tab

Gene Target & FDA approval also listed Patient View Drugs Tab Gene Target Gene Target & FDA approval also listed

Other Patient View Visuals Tissue Images Pathology Report Clinical Data

Security & Authentication User User Authentication Provided by Google Group CBTTC SU2C Public Data Set 1 Data Set 2 Data Set 3 Data Set 4 Data

Coming Attractions Timeline – Multiple samples per patient Support for PDX Variant Annotation & Prioritization More simplified clinical interface Isoform level information Connection to raw data and processing pipelines 30+ Active Developers from CHOP, MSKCC, DFCI, Princess Margeret, and the Hyve

Acknowledgements cBioPortal Consortium MSKCC DFCI Princess Margeret The Hyve CBTTC Collaborators Adam Resnick Alex Felmeister Tyler Rivera Jena Lilly Angela Waanderers Philip Allman CHOP cBioPortal+ Team Karthik Kalletla Anna Lu Kaitlyn Money CHOP/DBHi Collaborators Deanne Taylor Asif Chinwalla John Maris & SU2C

Thank You Visit Us : www.cbioportalplus.org Follow Us : @cBioPortal_Plus